Personalized Repetitive Transcranial Magnetic Stimulation (rTMS) in Cognitive Fluctuations of Dementia With Lewy Bodies (DLB): Proof of Concept

You may qualify if

• Male or female patient aged ≥ 45 years
• Enrolled in a social health insurance scheme
• Diagnosed with probable DLB according to McKeith et al. criteria, 2017, or McKeith et al. 2020 criteria for the prodromal stage
• A Mini Mental State Examination (MMSE; Folstein et al., 1983) score ≥ to 18 in the last 6 months (prodromal stage or a major neurocognitive disorder (dementia syndrome) at moderate stage)
• MMSE score ≥ to 15 at the inclusion visit
• Presence of clinically significant cognitive fluctuations
• Caregivers of eligible patients do have to be able to stay with the patient for at least 4 hours a day, 3 days a week, and have to be able to provide requested information and accompany the patient to the certain visits.
• The patient must be able to understand the objectives and risks of the study and has to be able to give dated and signed informed consent. In the case of a designed guardian or curator, the guardian or curator will sign the consent.
• For women of childbearing age, effective contraception throughout the study is required

You're excluded if

• History of generalized seizures (epilepsy)
• Pharmacological treatment for cognitive fluctuations in DLB with dose modifications that have taken place less than 2 months before the first visit of the protocol (anticholinesterase and neuroleptics)
• Anti-epileptic drug treatment "Keppra" (Levetiracetam)
• History of psychosis or severe depression unrelated to DLB
• History of brain surgery (tumour removal, electrode implantation, certain strokes as judged by the investigator, oedema...)
• Patients with any contraindication for MRI scans (claustrophobia, pacemaker, cochlear implant, mechanical heart valve, metallic prostheses, neurostimulators, other non-removably implanted electronic medical devices etc.)
• Subject unable to understand the aims and risks of the study and patients unable to give full informed consent
• Having a MMSE score \< to 18 in the last 6 months (prodromal stage or mild to moderate dementia)
• MMSE score \< to 15 at the inclusion visit
• Patients in an emergency or life-threatening situation
• Patients under court protection
• Pregnancy
• Breastfeeding
• Patients in exclusion period (determined by a previous or current study)

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-08-20